Automated Drug Discovery Workflows to Identify the Best Producing Clones with Highest Productivity

Overview

Antibodies are the ideal therapeutic biomolecule due to their ability to bind to a variety of targets with high affinity and specificity. Innovations in hybridoma and phage display technologies have allowed drug developers to exploit the natural diversity in antibodies, leading to the wide use of monoclonal antibodies (mAbs) in treating cancers, chronic inflammation, and infectious diseases. Whilst single B-cell screening has significantly evolved and is the main source for obtaining antigen-specific mAb sequences, hybridoma screening using semi-solid media still represents an important technology.

This technical note focuses on both methods within the antibody discovery workflow and the role CellCelector can play.

• Document type: Technical Note
• Page count: 8
• Read time: 6 minutes

Complete the Form to Access the Technical Note